Tuesday, November 14, 2023 10:04:04 AM
https://www.otcmarkets.com/filing/html?id=17053869&guid=ckJ-kWUD04t3dth#owvi_ex312_htm
General and administrative expenses of $792,696, for the nine months ended September 30, 2023, included a loan and accrued interest receivable impairment of $646,350. The $80,880 for the nine months ended September 30, 2022 consisted of overhead costs other than consulting fees, professional fees, and legal and accounting expenses.
The increase in operating expenses from 2022 to 2023, in addition to the impairment cost of $646,350 was due to costs associated with increased business activity.
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM